{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:59:53Z","timestamp":1785560393982,"version":"3.56.0"},"reference-count":26,"publisher":"Japan Atherosclerosis Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.5551\/jat.66182","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:09:19Z","timestamp":1776895759000},"page":"1030-1048","source":"Crossref","is-referenced-by-count":1,"title":["Association of Relative LDL-Cholesterol Reduction With Cardiovascular Outcomes After Percutaneous Coronary Intervention"],"prefix":"10.5551","volume":"33","author":[{"given":"Tetsuji","family":"Morishita","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui"},{"name":"Department of Internal Medicine, Matsunami General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Uzui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui"},{"name":"Department of Clinical Nursing, Faculty of Medical Sciences, University of Fukui"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiro","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ and Group JS: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207","DOI":"10.1056\/NEJMoa0807646"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ and Group JTS: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, 2009; 373: 1175-1182","DOI":"10.1016\/S0140-6736(09)60447-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hsia J, MacFadyen JG, Monyak J and Ridker PM: Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol \uff1c50 mg\/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol, 2011; 57: 1666-1675","DOI":"10.1016\/j.jacc.2010.09.082"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM and Investigators I-I: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Giugliano RP, Wiviott SD, Blazing MA, De Ferrari GM, Park JG, Murphy SA, White JA, Tershakovec AM, Cannon CP and Braunwald E: Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. JAMA Cardiol, 2017; 2: 547-555","DOI":"10.1001\/jamacardio.2017.0083"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, Committees OO and Investigators: Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Schubert J, Lindahl B, Melhus H, Renlund H, Leosdottir M, Yari A, Ueda P, James S, Reading SR, Dluzniewski PJ, Hamer AW, Jernberg T and Hagstrom E: Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study. Eur Heart J, 2021; 42: 243-252","DOI":"10.1093\/eurheartj\/ehaa1011"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Minami Y, Ako J, Tsujita K, Yokoi H, Ikari Y, Morino Y, Kobayashi Y and Kozuma K: Drug intervention as an emerging concept for secondary prevention in patients with coronary disease. Cardiovasc Interv Ther, 2024; 39: 223-233","DOI":"10.1007\/s12928-024-00994-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R and Cholesterol Treatment Trialists C: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 2005; 366: 1267-1278","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P and Gurbel PA: Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. JAMA, 2018; 319: 1566-1579","DOI":"10.1001\/jama.2018.2525"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E and Sabatine MS: Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA, 2016; 316: 1289-1297","DOI":"10.1001\/jama.2016.13985"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J and Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, Lee JB, Yang TH, Yoon J, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK and Investigators L: Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA, 2023; 329: 1078-1087","DOI":"10.1001\/jama.2023.2487"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O and Group ESCSD: 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020; 41: 111-188","DOI":"10.15829\/1560-4071-2020-3826"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, Ferranti Sd, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Sperling L, Virani SS and Yeboah J: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1082-e1143","DOI":"10.1161\/CIR.0000000000000625"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Okamura T, Tsukamoto K, Arai H, Fujioka Y, Ishigaki Y, Koba S, Ohmura H, Shoji T, Yokote K, Yoshida H, Yoshida M, Deguchi J, Dobashi K, Fujiyoshi A, Hamaguchi H, Hara M, Harada-Shiba M, Hirata T, Iida M, Ikeda Y, Ishibashi S, Kanda H, Kihara S, Kitagawa K, Kodama S, Koseki M, Maezawa Y, Masuda D, Miida T, Miyamoto Y, Nishimura R, Node K, Noguchi M, Ohishi M, Saito I, Sawada S, Sone H, Takemoto M, Wakatsuki A and Yanai H: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853","DOI":"10.5551\/jat.GL2022"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Ridker PM, Mora S, Rose L and Group JTS: Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J, 2016; 37: 1373-1379","DOI":"10.1093\/eurheartj\/ehw046"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kang D, Choi KH, Yang S, Kim H, Park TK, Lee JM, Cho J, Yang JH, Song YB, Choi SH, Gwon HC and Hahn JY: Clinical significance of low-density lipoprotein cholesterol percentage reduction and attained levels after percutaneous coronary intervention. CMAJ, 2025; 197: E442-E452","DOI":"10.1503\/cmaj.241713"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM and Investigators S: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2007; 38: 3198-3204","DOI":"10.1161\/STROKEAHA.107.493106"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Bangalore S, Fayyad R, Kastelein JJ, Laskey R, Amarenco P, DeMicco DA and Waters DD: 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Am J Med, 2016; 129: 384-391","DOI":"10.1016\/j.amjmed.2015.10.024"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Cho KH, Yang JH, Lee SY, Shin MH, Oh S, Kim MC, Sim DS, Hong YJ, Kim JH, Ahn Y, Lee JH, Kwun JS, Jeong YH, Hahn JY, Hwang JY, Jeong MH and Kim W: Long-term outcomes according to absolute value vs. percentage reduction in low-density lipoprotein cholesterol levels after acute myocardial infarction. Front Cardiovasc Med, 2025; 12: 1653447","DOI":"10.3389\/fcvm.2025.1653447"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, St\u00e5hle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW and Investigators S: Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 2009; 360: 961-972","DOI":"10.1056\/NEJMoa0804626"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O\u2019Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ and Initiative SDCfCT: 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018; 137: 961-972","DOI":"10.1161\/CIRCULATIONAHA.117.033502"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Morishita T, Uzui H, Mitsuke Y and Tada H: Relationship of body mass index to clinical outcomes after percutaneous coronary intervention. Eur J Clin Invest, 2022; 52: e13789","DOI":"10.1111\/eci.13789"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Morishita T, Uzui H, Nakano A, Fukuoka Y, Ikeda H, Amaya N, Kaseno K, Ishida K, Lee JD and Tada H: Association of plasma pentraxin-3 levels with coronary risk factors and the lipid profile: a cross-sectional study in Japanese patients with stable angina pectoris. Heart Vessels, 2018; 33: 1301-1310","DOI":"10.1007\/s00380-018-1191-8"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/8\/33_66182\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:49:13Z","timestamp":1785559753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/8\/33_66182\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66182","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]},"article-number":"66182"}}